MindMed rebrands to Definium Therapeutics; $412M cash; three Phase 3 readouts in 2026

Definium Therapeutics, Inc.

Preliminary cash and investments ~$412M as of Dec 31, 2025.
Name changed to Definium Therapeutics; new ticker DFTX effective Jan 13.
Three Phase 3 readouts for DT120 ODT (GAD/MDD) in 2026: Voyage (2Q), Panorama (2H), Emerge (mid-year).
Analyst Day in 2Q 2026 to highlight pipeline and path to commercialization.
DT402 Phase 2a for autism spectrum disorder dosed first patient; initial data in 2026.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Definium Therapeutics, Inc.: Changed company name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc. via alteration of Notice of Articles (effective 2026-01-09).

Change: charter amendment
Effective: 2026-01-09

Exact text from the filing

On January 9, 2026, the Company filed a Notice of Alteration with the Province of British Columbia Registrar of Companies to alter its Notice of Articles to change the Company’s corporate name from “Mind Medicine (MindMed) Inc.” to “Definium Therapeutics, Inc.”

View on SEC.gov

Browse all governance changes →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-009854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.